Compare NTIC & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | OKYO |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United Kingdom |
| Employees | 94 | 5 |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 71.4M |
| IPO Year | 1996 | 2021 |
| Metric | NTIC | OKYO |
|---|---|---|
| Price | $7.75 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 11.0K | ★ 79.3K |
| Earning Date | 04-09-2026 | 07-18-2025 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.35 | $1.28 |
| 52 Week High | $10.03 | $3.20 |
| Indicator | NTIC | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 40.81 |
| Support Level | $7.88 | $1.31 |
| Resistance Level | $8.09 | $1.72 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 66.67 | 26.47 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.